According to an article in the Financial Times, Roche UK have decided not to renew their membership of the ABPI (Association of the British Pharmaceutical Industry). This follows the company being suspended last year for serious breaches of practice relating to selling its slimming drug Xenical, and also issues around incentives to patients taking its cystic fibrosis drug.
This new move highlights the recurring question of what the organisation can do when a member company breaches its code of practice, when it has no power other than to suspend its members?
A Roche statement in the FT said it had “decided not to rejoin the ABPI for the time being” and that it would continue to work within the code of practice.
1 comment:
I chanced upon to view your blog and found it very interesting. Great ... Keep it up!
Post a Comment